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FOR THE HEALTH ABC STUDY
OBJECTIVE — Poorperipheralnervefunctionisprevalentindiabetesandolderpopulations,
and it has great potential to contribute to poor physical performance.
RESEARCH DESIGN AND METHODS — Cross-sectional analyses were done for the
Health, Aging, and Body Composition (Health ABC) Study participants (n  2,364; 48% men;
38% black; aged 73–82 years). Sensory and motor peripheral nerve function in legs/feet was
assessed by 10- and 1.4-g monoﬁlament perception, vibration detection, and peroneal motor
nerveconductionamplitudeandvelocity.TheHealthABClower-extremityperformancebattery
was a supplemented version of the Established Populations for the Epidemiologic Studies of the
Elderlybattery(chairstands,standingbalance,and6-mwalk),addingincreasedstandduration,
single foot stand, and narrow walk.
RESULTS — Diabetic participants had fewer chair stands (0.34 vs. 0.36 stands/s), shorter
standing balance time (0.69 vs. 0.75 ratio), slower usual walking speed (1.11 vs. 1.14 m/s),
slower narrow walking speed (0.80 vs. 0.90 m/s), and lower performance battery score (6.43 vs.
6.93) (all P  0.05). Peripheral nerve function was associated with each physical performance
measure independently. After addition of peripheral nerve function in fully adjusted models,
diabetes remained signiﬁcantly related to a lower performance battery score and slower narrow
walking speed but not to chair stands, standing balance, or usual walking speed.
CONCLUSIONS — Poor peripheral nerve function accounts for a portion of worse physical
performance in diabetes and may be directly associated with physical performance in older
diabeticandnondiabeticadults.Theimpactof
peripheral nerve function on incident disabil-
ity should be evaluated in older adults.
Diabetes Care 31:1767–1772, 2008
D
iabetes is associated with self-
reported and objective physical
performance measures of func-
tional limitation in U.S. adults (1). Poor
peripheral nerve function may play a role
in reduced physical function in older di-
abetic adults (2,3). The incidence (4) and
prevalence of poor peripheral nerve func-
tion are higher in older adults, even
among those without diabetes (4–7). In
the U.S. for 1999–2000, 28% of adults
aged 70–79 years and 35% of adults aged
80 years had peripheral neuropathy
based on a simple screen for reduced sen-
sation at the foot (7). We previously
found that diabetes was associated with
subclinical functional limitation and
physical performance in our cohort, al-
though peripheral nerve function mea-
sures were not completed then (8).
Toourknowledge,therelationshipof
combined sensory and motor peripheral
nerve function to objective physical per-
formancehasnotbeeninvestigatedinam-
bulatory, community-dwelling older
adults. We evaluated the distribution of
sensory and motor peripheral nerve func-
tion in older diabetic and nondiabetic
adults and the relationship of peripheral
nerve function to objective physical per-
formance. We hypothesized that sensory
and motor peripheral nerve function ex-
plained the relationship of poor physical
performance in an older community-
based population, both with and without
diabetes.
RESEARCH DESIGN AND
METHODS— Participants were from
well-functioning older white and black
adults (n  3,075; 48.4% male; 41.6%
black), aged 70–79 years at the 1997–
1998baselineexamination,intheHealth,
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ABC) Study, with a follow-up examina-
tion in 2000–2001. Health ABC is an on-
going prospective cohort study
investigating changes in body composi-
tionasacommonpathwaybywhichmul-
tiple diseases contribute to disability.
Participants were recruited from mailings
in Pittsburgh, Pennsylvania, and Mem-
phis,Tennessee,to1)arandomsampleof
white Medicare beneﬁciaries and 2) all
age-eligibleblackcommunityresidents.A
telephone interview determined eligibil-
ity, deﬁned as no difﬁculty in walking a
quarter of a mile (400 m), climbing 10
steps, or performing activities of daily liv-
ing; free of life-threatening cancers with
no active treatment within the past 3
years; and planning to remain within the
study area for 3 years. Participants pro-
vided informed consent before examina-
tions, approved by institutional review
boards at the University of Pittsburgh
and the University of Tennessee Health
Science Center. Of 3,075 participants at
baseline, 2,479 of 2,493 (99.4%) with a
clinic or home 2000–2001 examination
had 1 component of the physical per-
formance battery. The remaining cohort
had telephone follow-up (n  282), were
deceased (n  187), withdrew (n  11),
or missed the examination (n  102). We
excluded participants missing all periph-
eral nerve function measures (n  87) or
fasting blood glucose results (n  23) or
with diabetes onset at 20 years of age
(n  5). We included 2,364 participants
(761 white men, 381 black men, 701
white women, and 521 black women),
representing 76.9% of baseline partici-
pants and 94.8% of those with a 2000–
2001 examination.
Sensory and motor peripheral nerve
function
Peripheral nerve function measures (on
rightlegunlesscontraindicated)included
monoﬁlament testing (reduced sensation
deﬁned as inability to feel three of four
touches at the great toe for both 1.4- and
10-g monoﬁlaments), average vibration
threshold in micrometers (VSA-3000 vi-
bratory sensory analyzer; Medoc), and
peroneal motor nerve conduction ampli-
Table 1—Descriptive characteristics by diabetes status and sex
Men Women
Diabetes No diabetes Diabetes No diabetes
n 273 869 210 1,012
Age (years) 76.8  2.7 76.7  2.9 76.1  2.8 76.5  2.9
Black race (%) 41.0* 31.0 65.7† 37.8
Diabetes duration (years) 11.3  11.1 — 11.0  11.2 —
Diabetes duration 5 years (%) 54.8 — 55.4 —
A1C (%) 7.1  1.4† 5.3  0.4 7.1  1.5† 5.4  0.4
A1C 7% (%) 45.1† 0.3 45.7† 0.3
Lifestyle characteristics
Current smoker (%) 5.4 7.3 6.5 7.2
Drinking frequency 1/week (%) 59.6 61.7 26.7† 47.6
Physical activity (kcal   kg
1   week
1) 2.0* 3.4 0.5† 1.8
Body composition and physical ability
Height (cm) 173.1  6.6 172.6  6.7 159.1  5.2 158.8  63.4
BMI (kg/m
2) 28.2  4.0† 26.8  4.0 30.0  5.5† 27.2  5.3
Bone free lean mass (kg) 56.7  7.4† 53.5  6.7 42.6  6.3† 38.7  5.5
Total fat mass (kg) 25.7  7.8† 23.3  7.1 30.7  9.0† 27.5  9.0
Quadriceps strength (Nm) 113.5  31.1* 118.4  31.7 75.6  22.7 72.8  20.8
Recurrent falls in past year (%) 9.2 7.4 11.0 8.0
Comorbidities
Cardiovascular disease history (%) 25.5 22.1 19.6† 10.4
Cerebrovascular disease history (%) 8.2 6.0 7.2 6.9
Peripheral arterial disease history (%) 7.6 4.9 4.5 3.1
Ankle-arm index 0.9 (%) 23.7† 14.4 24.7† 14.6
Hypertension (%) 78.0* 69.4 83.8† 73.0
Systolic blood pressure (mmHg) 140.2  21.4 138.3  20.5 145.5  23.8 142.1  21.8
Diastolic blood pressure (mmHg) 73.4  11.3 75.0  10.7 73.1  11.2 74.0  11.4
Cholesterol (mg/dl) 177.9  36.7* 181.6  31.6 198.5  38.8 202.8  38.3
Retinal disease/retinopathy (%) 6.6 6.9 9.0 6.1
Glaucoma (%) 15.8 12.0 22.1† 9.7
Cataracts (%) 44.2 39.7 58.0 53.6
Cystatin-C (mg/l) 1.1  0.3* 1.0  0.3 1.0  0.3 1.0  0.2
Creatinine 1.5 men/1.3 women (%) 12.2* 7.2 9.3† 3.2
CES-D depression index 6.3  6.1* 5.4  5.8 8.3  7.2* 6.9  6.7
Knee pain, most days/month (%) 23.4* 15.9 22.9 23.6
Osteoarthritis (%) 7.0 8.3 7.7 12.3
Data are means  SD for continuous values and medians for those with large ranges. *P  0.05; †P  0.001 for diabetic vs. nondiabetic participants within sex
groups.
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tion potential [CMAP]) and velocity in
meters per second (nerve conduction ve-
locity[NCV])fromthepoplitealfossaand
ﬁbular head to ankle (NeuroMax 8;
XLTEK).
Physical performance
The Health ABC performance battery
(score range 0–12) was a supplemented
version of the lower-extremity battery
from the Established Populations for the
Epidemiologic Studies of the Elderly (ﬁve
repeated chair stands, semi-tandem and
full-tandem stands for balance, and a 6-m
walk for usual gait speed) (9), adding in-
creased stand duration (30 s), a 30-s sin-
gle leg stand, and a narrow walk test of
balanceusingthesamecourseasforusual
gait speed (10). The standing balance ra-
tio was derived by dividing summed
times for all stands by maximal stand
time.
Diabetes
Diabetes was deﬁned as self-reported
physician diagnosis that was not during
pregnancy, hypoglycemic medication
use,orfastingglucose126mg/dl(7.0
mmol/l) after an overnight fast (8 h). Of
2,364 participants, 20.4% (425 with di-
agnosed diabetes and 58 with fasting
glucose 126 mg/dl) had diabetes.
Body composition and strength
Height was measured using a stadiom-
eter. Weight was measured with a cali-
brated balance beam scale. Total whole-
body bone mineral-free lean mass and fat
mass were assessed by dual-energy X-ray
absorptiometry (Hologic 4500A; Ho-
logic) in 2001–2002. Knee extension
strength (on the right leg unless contrain-
dicated) was measured concentrically at
60°/s on an isokinetic dynamometer (125
AP dynamometer; Kin-Com) in three to
six trials. Quadriceps strength was calcu-
lated as the mean maximal torque pro-
duced (Newton-meter) between 90° and
30° of knee extension from the three best
trials.
Other measures
Health histories included smoking
(1999–2000), alcohol consumption
frequency at baseline, osteoarthritis
(1999–2000), diabetes-related compli-
cationsatbaseline(peripheralarterialdis-
ease, cerebrovascular disease [transient
ischemic attack/stroke], cardiovascular
disease [bypass/coronary artery bypass
graft,carotidendarterectomy,myocardial
infarction, angina, or congestive heart
failure], and eye diseases [1999–2000;
retinopathy/retinal disease, cataracts, or
glaucoma]). Medications from the prior
week were inventoried in 1999–2000,
coded with Iowa Drug Information Sys-
tem ingredient codes (11), and classiﬁed
forcentralnervoussystemeffects.Weekly
physical activity from walking and stair
climbing (kilocalories per kilogram per
week), falling in the prior 12 months
(none,one,ortwoormore),kneepainon
most days in the past month, and depres-
sive symptoms on the Center for Epide-
miologic Studies Depression (CES-D)
scale (12) were determined by an inter-
viewer-administered questionnaire. Cog-
nitive function was measured with the
ModiﬁedMini-MentalStateExamination,
and attention, psychomotor speed, and
executive function were measured with
the Digit Symbol Substitution test (13).
Cystatin-C (1 mg/dl) and serum creati-
nine 1.5 mg/dl for men and 1.3
mg/dl for women deﬁned renal insufﬁ-
ciency at baseline. Total cholesterol was
measured after a 8-h fast. Hyperten-
sion was deﬁned through self-reported
physician diagnosis, medication use,
and/or blood pressure. Ankle-brachial
index 0.9 assessed subclinical cardio-
vascular disease.
Statistical analyses
Differences in prevalence and univariate
associations were tested separately by di-
abetes status and race within sex using
Pearson 
2 methods and Fisher’s exact
test when appropriate. For continuous
variables, nonparametric one-way Mann-
Whitney tests were performed for non-
normal distributions.
Means of physical performance mea-
sures were calculated with ANCOVA by
diabetes status and adjusted for demo-
graphic factors and peripheral nerve
function (monoﬁlament detection, av-
erage vibration threshold, CMAP, and
NCV). Separate models were used for
usual walking speed, narrow walking
speed, chair stands per second, stand-
ing balance ratio, and performance bat-
tery score. Each peripheral nerve
function measure was entered as an in-
dividual variable, as each represented a
distinct component of nerve function
with modest correlation between mea-
sures (r  0.03–0.22, adjusted for age,
sex, and race). Vibration threshold was
also analyzed by quartiles because of its
skewed distribution to very low or very
high threshold values, although results
did not change.
Stepwise multiple linear regression
was performed with physical perfor-
mance measures as outcomes and diabe-
tes and peripheral nerve function as the
independent variables of interest, while
adjusting for demographic variables and
variablesdetailedin OTHER MEASURES.Mod-
els met underlying assumptions and were
built progressively by entering variables
stepwise as follows: diabetes, demo-
graphic factors, body composition,
strength, physical function risk factors,
diabetes-related comorbidities, and ﬁ-
nally peripheral nerve function. Diabetes
and demographic factors were included
in all models, and remaining variables
were removed in a stepwise manner at
P  0.10. Models were run excluding di-
abetic participants to determine whether
relationshipsremainedconsistent.Diabe-
tes severity was assessed by replacing di-
abetes with dummy variables for either
diabetes duration (5 years, 5 years, or
no diabetes) or A1C (7%, 7%, or no
diabetes) in the ﬁnal models. Multicol-
linearity for independent variables was
assessed using the variance inﬂation fac-
Table 2—Peripheral nerve function descriptive characteristics by diabetes status and sex
Men Women
Diabetes No diabetes Diabetes No diabetes
n 273 869 210 1,012
No 10-g monoﬁlament
detection (%)
19.2* 10.4 6.7 5.6
No 1.4-g monoﬁlament
detection (%)
61.9* 50.4 44.0 38.1
Average threshold
vibration ()
67.8  39.4* 56.3  34.8 48.7  35.2† 42.7  31.3
CMAP (mV) 2.6  1.8* 3.0  1.9 3.5  2.1 3.6  2.0
NCV (m/s) 40.9  4.9† 42.1  5.0 43.7  4.7† 44.8  5.7
*P  0.001; †P  0.05 for diabetic vs. nondiabetic participants within sex groups.
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variance not accounted for by other inde-
pendent variables; no VIF was 10 and
the mean VIF for each regression model
was 2 (14). Percent change in perfor-
mance measures due to diabetes was
calculated using the formula [(unstand-
ardized  for diabetes) (unit change in
diabetes)/performance measures mean
for entire sample] 	 100; 95% CIs were
calculated using the formula {[(unstand-
ardized  for diabetes) (unit change in
diabetes)  (SE of  for diabetes) (1.96)]/
performance measures mean for entire
sample}	100. Data were analyzed using
SPSS (SPSS, Chicago, IL) statistical
software.
RESULTS— Black participants were
more likely to have diabetes than white
participants (Table 1). The mean diabetes
duration was 11 years; 55% of partici-
pants had duration of 5 years and 45%
had A1C 7%. Diabetic participants had
higher BMI, higher lean mass, higher fat
mass, lower physical activity, more hy-
pertension, worse ankle-arm index,
highercreatinine,andahigherCES-Dde-
pression index than nondiabetic partici-
pants. Diabetic men had higher
cystatin-C levels, lower cholesterol levels,
and more knee pain in the past 30 days
than nondiabetic men. Diabetic women
were more likely to report cardiovascular
disease history, glaucoma, and less fre-
quentdrinking.Diabeticmenhadless10-
and1.4-gmonoﬁlamentdetection,higher
average threshold vibration, lower
CMAP, and lower NCV than nondiabetic
men (Table 2). Diabetic women had
higher average threshold vibration and
lower NCV than nondiabetic women.
Olderadultswithdiabeteshadslower
chairstandrates,shorterstandingbalance
times,slowerusualwalkingspeed,slower
narrow walking speed, and lower physi-
cal performance battery score compared
with nondiabetic adults (Table 3). After
adjustment for peripheral nerve function,
the mean value of each performance mea-
sure improved for both those with and
without diabetes (Table 3).
In adjusted analyses, diabetes was as-
sociatedwithworsephysicalperformance
for all measures except chair stands
(Table 4, model 1). With the addition of
peripheralnervefunctionformodel2,di-
abetes was not associated with usual
walking speed (from 2.1 to 1.7% lower;
20.8%  attenuation) or the standing bal-
anceratio(from4.6to3.4%lower;26.5%
 attenuation) and was attenuated, al-
thoughitremainedsigniﬁcantlyrelatedto
lower performance battery score (from
4.8 to 3.6% lower; 25.1%  attenuation)
and slower narrow walking speed (from
11.4 to 10.1% lower; 11.4%  attenua-
tion). Impaired monoﬁlament detection
was related to lower performance battery
score, slower narrow walking speed, and
fewer chair stands. Higher average vibra-
tion threshold was related to lower per-
formance battery scores, slower usual
walking speed, and shorter standing bal-
ance times. Lower CMAP was related to
lower performance battery scores, slower
usual and narrow walking speed, and
shorter standing balance times. Lower
NCV was related to fewer chair stands.
When ﬁbular head rather than popliteal
fossa CMAP and NCV were included, all
relationships were similar. Excluding di-
abetic participants did not alter associa-
tions, except for monoﬁlament detection
and the performance battery score.
Asreportedinourpreviousstudy(8),
greater diabetes severity was signiﬁcantly
associated with worse physical perfor-
mance, with results for diabetic adults
withlessseverediseasebeingnotdifferent
from those for nondiabetic adults. Diabe-
tes severity was related to lower perfor-
mance battery scores (A1C 7% and
duration 5 years), slower usual walking
speed (A1C 7%), and narrow walking
speed (duration 5 years), and shorter
standing balance times (A1C 7% and
duration 5 years) than those for non-
diabetic adults. Relationships between
diabetes severity and physical perfor-
mance did not affect associations with
peripheral nerve function.
CONCLUSIONS— Our results indi-
cate that poor peripheral nerve function
explains a portion of the association of
diabetes with physical disability. In this
population of community-dwelling older
adults, both poor sensory and motor pe-
ripheral nerve function were indepen-
dently associated with worse physical
performance. These ﬁndings are impor-
tant because studies of physical perfor-
mance in older adults typically do not
assess peripheral nerve function. Ad-
justments for lean mass and strength
did not eliminate relationships, sug-
gesting that peripheral nerve function
affects physical performance directly
rather than indirectly through associa-
tions with muscle.
Sensory nerve assessments were re-
lated to several performance measures.
Lack of 10-g monoﬁlament detection is
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1770 DIABETES CARE, VOLUME 31, NUMBER 9, SEPTEMBER 2008generally associated with clinical disease
that is predictive of future foot ulcers
(15). In addition, perception with the
more sensitive 1.4-g monoﬁlament,
which detects subclinical neuropathy,
andreductioninvibrationthresholdwere
related to performance.
CMAP of the peroneal motor nerve
was related to all performance measures
except chair stands. We are uncertain as
to why NCV showed weaker relation-
ships; however, we did not examine any
nerve supplying the proximal muscula-
ture of the lower limbs. Fibular head
nerve conduction results were consistent
withthoseforthepoplitealfossa,suggest-
ing that entrapment at the knee does not
explain associations with physical perfor-
mance.LowerNCVwasnotrelatedtofast
walking speed in the InCHIANTI Study,
an Italian cohort aged 60 years, al-
though it was related to longer 400-m
walk time and lower summary perfor-
mancescore(16).LowCMAPisrelatedto
nerve axonal damage and low NCV is re-
lated to nerve demyelination (17). Inter-
estingly, the InCHIANTI Study showed
that lower peroneal CMAP, but not NCV,
was independently associated with lower
calf muscle density (18). Our relation-
ships of poor peripheral nerve function
and physical performance may be similar
to the relationships with muscle. Severe
diabetic peripheral neuropathy is clearly
related to muscle atrophy, with neuropa-
thyscoreandmusclevolumebeinghighly
correlated (19,20). Proximal muscle
weaknesswithinabilitytostandisusually
the result of proximal motor neuropathy
of the demyelinating variety, especially in
older adults (21).
At the Health ABC Study baseline, di-
abetes, particularly with longer duration
or poor control, was associated with sub-
clinical functional limitation (8) and re-
duced strength (22), although we had no
measure of peripheral nerve function
then. Previous studies of older diabetic
adults indicated that worse peripheral
nervefunctionisrelatedtopoorerbalance
and slower gait speed (2,3). Our results
suggest that peripheral nerve impair-
ments affect certain types of physical
functioning more than others and are
consistent with those of a study of dis-
abled women aged 65 years, which
showedthatlowersummaryperformance
score,poorbalance,andslowergaitspeed
were associated with worse sensory nerve
function and an attenuation of diabetes
and physical performance after adjust-
ment for nerve function (3,23). In older
Italian adults, distal symmetrical neurop-
athy was associated with a twofold in-
creased risk of physical performance
decline independent of diabetes (24).
Ourstudyisuniqueinitsinclusionof
state-of-the-art standardized sensory and
motor peripheral nerve function assess-
ments and objective physical perfor-
mance. Peripheral nerve function
measures were limited to large ﬁber
nerves rather than small ﬁber nerves. Ide-
ally, nerve conduction studies test multi-
ple nerves to conﬁrm polyneuropathy.
The peroneal nerve, rather than the sural
nerve, was selected because it is a motor
nerve and more likely to have a response
in older adults (5). We controlled for
many factors potentially affecting both
our outcome and exposure of interest, in-
cluding lean mass and quadriceps
strength, to account for decreased physi-
cal functioning occurring indirectly
through loss of muscle mass and falls. Pe-
ripheral nerve function was probably
worse in nonstudy participants and
Health ABC Study participants without a
follow-up; therefore, results may apply
only to ambulatory community-dwelling
older adults. Future studies are needed to
address these associations across wider
ages of older adults (including those with
worse physical function) and to evaluate
whether peripheral nerve function in the
upper extremities contributes to upper-
extremity performance. Prospective stud-
ies, which we are conducting, are needed
to address causality of associations be-
tween peripheral nerve function and
physical performance.
Insummary,thismultiethnicstudyof
Table 4—Multivariate linear regression models for the performance battery, usual walk, narrow walk, standing balance, and chair stands
Performance
battery score
(0–12)
Usual walking
speed (m/s)
Narrow walking
speed (m/s)
Standing balance
ratio
Chair stands (per
s)
 P value  P value  P value  P value  P value
Final model, no peripheral nerve
function variables
Diabetes 0.332 0.001 0.024 0.07 0.105 0.001 0.034 0.04 0.010 0.10
Final model, with peripheral nerve
function variables
Diabetes 0.250 0.009 0.019 0.10 0.094 0.001 0.025 0.10 0.007 0.10
Monoﬁlament detection
(no/10-g/1.4-g)
0.174 0.003 — 0.10 0.049 0.006 — 0.10 0.015 0.007
Average vibration threshold () 0.004 0.001 0.0005 0.005 — 0.10 0.001 0.001 — 0.10
CMAP (mV) 0.105 0.001 0.008 0.004 0.029 0.001 0.014 0.001 — 0.10
NCV (m/s) — 0.10 — 0.10 — 0.10 — 0.10 0.001 0.09
Final models were additionally adjusted for age (all), race (all), sex (all), study site (all), height (chair stands), total fat mass (all), quadriceps strength (all), current
smoking (performance battery and standing balance ratio), medications with central nervous system effects (performance battery, usual walking speed, standing
balance ratio, and chair stands), physical activity (performance battery and usual walking speed), falls (performance battery, narrow walking speed, and standing
balanceratio),osteoarthritis(standingbalanceratio),kneepain(chairstands),prevalentcerebrovasculardisease(performancebattery,usualwalkingspeed,narrow
walking speed, and chair stands), blood pressure (performance battery, usual walking speed, standing balance ratio, and chair stands), cholesterol (narrow walking
speed), cataracts (performance battery, usual walking speed, and chair stands), glaucoma (performance battery and standing balance ratio), high creatinine
concentration (performance battery), high cystatin-C concentration (performance battery, usual walking speed, standing balance ratio, and chair stands), CES-D
(all), Modiﬁed Mini-Mental State Examination (performance battery, narrow walking speed, and standing balance ratio), and Digit Symbol Substitution (all).
Variables above and additional variables listed in RESEARCH DESIGN AND METHODS were removed from models in a stepwise manner at P  0.10.
Strotmeyer and Associates
DIABETES CARE, VOLUME 31, NUMBER 9, SEPTEMBER 2008 1771older men and women showed consistent
associations of poor sensory and motor
peripheral nerve function and worse ob-
jective physical performance. Consider-
ingthehighprevalenceofpoorperipheral
nerve function in older adults, in our
study and in the U.S. (7), and the current
diabetes epidemic, peripheral nerve im-
pairments are an unappreciated problem
in the elderly population. Peripheral
nerve function should be evaluated when
one is studying physical performance in
older adults. Whether poor peripheral
nerve function will affect future disability
in diabetic and nondiabetic older adults
needs to be examined, and longitudinal
data are currently being collected for our
cohort.
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